More Business Wire
View Older Stories View Newer Stories-
80% of Individual Contributors Say Their Manager’s Approach to AI is Hands-Off, FranklinCovey Research Finds
-
Logitech Files Annual Report on Form 10-K
-
Aulos Bioscience Reports Positive Phase 2 Data for Imneskibart in Doublet Checkpoint Inhibitor-Refractory Metastatic Melanoma at 2026 ASCO Annual Meeting
-
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
-
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
-
Agendia to Present New FLEX Study Data at ASCO 2026 Supporting NCCN Clinical Practice Guidelines in Oncology Update Recognizing MammaPrint for Guiding Anthracycline Use in Early-Stage Breast Cancer
-
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
-
Dell Technologies to Present at Investor Conference in June
-
Obsidian Therapeutics to Present Phase 2 Clinical Data for OBX-115 in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting
-
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
-
A2 Biotherapeutics Presents Safety and Efficacy Data from the EVEREST-2 Clinical Study, Including Update on the First Complete Response to CAR T-Cell Therapy in a Patient with Non-Small Cell Lung Canc
-
858 Therapeutics Announces Initial Data from First-in-Human Phase 1/2 Trial of PARG Inhibitor ETX-19477 to be Presented at 2026 ASCO Annual Meeting
-
Artera Presents Multiple ASCO 2026 Abstracts on Multimodal AI (MMAI) Risk Stratification and Treatment Decisions in Cancer
-
New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
-
Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026
-
Flatiron Health Brings 25+ Research Acceptances and Next-Generation Capabilities to ASCO 2026
-
Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting
-
Ingenia Therapeutics, a Clinical-Stage Biotechnology Company, Has Received Approval for an Initial Public Offering on the Korea Exchange (KRX)
-
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
-
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
-
City of Hope Researchers Present Advances in Targeted Therapies, Microbiome Science and Blood Cancers at ASCO 2026
-
Daytona International Speedway to Install State-of-the-Art Musco LED Lighting System, Setting New Global Standard for Motorsports Venues
-
Mayville Engineering Company Announces Closing of Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares of Common Stock
-
Hour Children and Mental Health Innovations Teams Win Morgan Stanley’s 2026 Strategy Challenge Supporting Nonprofits in the U.S. and the UK
-
Matador Resources Company Announces Successful Acquisitions in Federal Lease Sale
-
Align Technology Hosts 400 Doctors at 2026 Invisalign® EMEA Ortho Summit Featuring Digital Orthodontic Solutions Focused on Clinical Indications and Upcoming Align Innovations
-
UiPath Named a Leader in Document Mining and Analytics Platforms by Independent Research Firm
-
GitLab 19.0 Extends Intelligent Orchestration to Close the Gap Between Writing Code and Shipping It
-
Hyatt to Present at Upcoming Investor Conferences
-
Falcon’s Beyond Lists Series B Preferred Stock on Nasdaq
-
BlackSky to Participate at Three Upcoming Investor Conferences
-
Radian CEO Rick Thornberry Announces Intent to Retire; Board Appoints Mike Weinbach as His Successor
-
Phibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference
-
Cencora Announces Updated Fiscal Year 2026 Financial Outlook
-
The Standard and Pacific Guardian Life Announce Entry into Agreement to Transition Individual Annuities Business
-
Elastic to Present at Upcoming Investor Conferences
-
GCI Liberty Completes Name Change to Liberty Capital Corporation
-
Exit Partners Advises Casa de Perrin on Strategic Sale to Curated Events
-
Copart Reports Third Quarter Fiscal 2026 Financial Results
-
Assurant Board of Directors Declares Quarterly Dividend of $0.88 per Common Share
-
Trinity Industries, Inc. Declares Quarterly Dividend
-
American Tower Corporation Declares Quarterly Distribution
-
Omega Announces Its Planned Leadership Transition
-
TechnipFMC to Speak at Bernstein 42nd Annual Strategic Decisions Conference
-
Universal Corporation Announces Conference Call
-
MFS Municipal Closed-End Funds Announce Closing Date for Reorganization and Change of Investment Adviser
-
Tanger Releases 2025 Impact Report
-
Radian Announces Results of 2026 Annual Meeting of Stockholders and Approves Regular Quarterly Dividend on Common Stock
-
Neptune Launches Atlas+, an AI-Powered Platform Experience Designed to Turn Insurance Agents into Super Agents
-
JPMorgan Chase Financial Company LLC Declares Quarterly Coupon on Alerian MLP Index ETN
